Pfizer Halts Development of Lipid-Lowering Drug
By

By
Pfizer has halted the global clinical development program for bococizumab, its investigational proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i) that was being developed as a lipid-lowering agent to treat…

Kaléo Re-Launches Epinephrine Auto-Injector
By

By
Kaléo, a privately held pharmaceutical company headquartered in Richmond, Virginia, has said it will reintroduce its Auvi-Q (epinephrine injection, USP) auto-injector, for treating severe allergic reactions, to the US market…

Daiichi Sankyo, Portola Expand Drug Pact in $33 Million Deal
By

By
Daiichi Sankyo has expanded its existing clinical collaboration agreement with Portola Pharmaceuticals, a South San Francisco-based biopharmaceutical company, to develop AndexXa (andexanet alfa) as an antidote for edoxaban, Daiichi Sankyo’s…

Aralez Completes Toprol-XL and Generic Acquisitions from AstraZeneca
By

By
Aralez Pharmaceuticals, a specialty pharmaceutical company headquartered in Mississauga, Ontario, Canada, has completed its acquisition of the US rights to Toprol-XL (metoprolol succinate) and its authorized generic, which are used…

Signal Genetics, Miragen to Merge for Micro-RNA Drugs
By

By
Signal Genetics, a Carlsbad, California- based commercial-stage molecular diagnostic company, and Miragen Therapeutics, a Boulder, Colorado-based privately-held biopharmaceutical company have entered into a definitive merger agreement under which the stockholders…

BMS Announces Plans To Evolve Operating Model, Including Manufacturing
By

By
As part of its third-quartern earnings release, Bristol-Myers Squibb announced what it termed “an evolution of its operating model” in the near and long term. Without providing specifics, the company…

Allergan Names New Chairman
By

By
Allergan has appointed Brenton L. Saunders as chairman of the Allergan’s Board of Directors replacing Paul Bisaro, who has served as executive chairman since July 1, 2014. Bisaro will remain…

Allergan To Acquire Motus Therapeutics For $200 Million
By

By
Allergan has exercised an option to acquire Motus Therapeutics, a biopharmaceutical company developing peptide therapeutics for treating gastrointestinal disorders and a wholly owned subsidiary of Rhythm Holding Company. The key…

Teva, IBM Expand Partnership in Digital Health
By

By
Teva Pharmaceutical Industries has expanded its existing global e-Health alliance with IBM with a focus on two key healthcare challenges: the discovery of new treatment options and improving chronic disease…

Mylan Launches Generic Versions of Daiichi Sanyko’s Antihypertensive Drugs
By

By
Mylan N.V. has announced the US launches of the generic versions of two antihypertensive drugs by Daiichi Sankyo, Benicar and Benicar HCT, olmesartan medoxomil tablets, 5 mg, 20 mg and…